The US Court of Appeals for the Federal Circuit today dismissed Amgen’s appeal of a previous district court ruling that denied its motion to compel discovery from Hospira in a Biologics Price Competition and Innovation Act (BPCIA) litigation.
The US Court of Appeals for the Federal Circuit today dismissed Amgen’s appeal of a previous district court ruling that denied its motion to compel discovery from Hospira in a Biologics Price Competition and Innovation Act (BPCIA) litigation.
In appealing the decision, Amgen had argued that, unless it was provided discovery of Hospira’s manufacturing process for epoetin alfa (Epogen), its right to sue over the cell-culture patents it holds for the drug would be thwarted. It alternatively sought a writ of mandamus, which would compel discovery.
The court, however, said that it lacked jurisdiction over the district court’s order, and found that Amgen failed to satisfy the prerequisites necessary for such a writ, calling it “a drastic remedy reserved for the most ‘extraordinary causes,’” in which the party has no other means of relief, and has demonstrated that it has a legal right to the writ by “clear and indisputable” means.
The court took the position that, barring an injunction under federal law (which the Supreme Court’s ruling in Sandoz v Amgen rendered unavailable), Amgen could have sought relief under state law (though it did not), sued for patent infringement, or coerced information from Hospira by bringing suit on its cell-culture patents. Moreover, the decision indicated, the Supreme Court appears to have provided for the possibility of the sponsor’s filing suit upon an applicant’s failure to disclose information.
The court stated that “the denial of discovery in this case does not undermine the purpose of the BPCIA," and that the district court was correct in its decision to deny Amgen’s motion.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.